Radiation oncology vendor Elekta has launched a new study to assess the outcomes of patients who undergo MR-guided radiation therapy (MR/RT) with Elekta's Unity system at various cancer centers around the world.
The research is known as the Multi-Institutional Organization for Multiple Outcome Evaluation of Radio Therapy Using MR-Linac (MOMENTUM). It is designed to generate data that will pave the way for safe, fast, and evidence-based integration of MR/RT into everyday clinical practice, the company said. Prior research has shown that Elekta's Unity MR/RT device can improve tumor control, and the MOMENTUM study will demonstrate the extent to which these capabilities translate into prolonged disease-free survival and better quality of life.
The international Elekta MR-Linac Consortium, which comprises leading experts in radiation therapy, oncology, epidemiology, and medical physics, will lead the study.
Elekta received U.S. Food and Drug Administration (FDA) clearance for Unity in December 2018 and the CE Mark in Europe in June 2018.
